S-1 plus sorafenib for the treatment of advanced hepatocellular carcinoma.
CONCLUSION: This systematic review suggests that S-1 plus sorafenib showed modest clinical efficacy and tolerable toxicity profile in patients with advanced HCC. The recommended dose of S-1 and sorafenib was 80 or 64 mg/m(2)/day and 800 mg/day, respectively.
PMID: 28039697 [PubMed - in process]
Source: Journal of B.U.ON. - Category: Cancer & Oncology Tags: J BUON Source Type: research
More News: Cancer | Cancer & Oncology | Carcinoma | Databases & Libraries | Hepatitis | Hepatitis B | Hepatocellular Carcinoma | Liver | Liver Cancer | Study | Thrombocytopenia | Toxicology | Urology & Nephrology